Consensus is for FY25 revenue $871.56M. Revenue outlook includes in-line products, potential new product launches, and royalty revenue from Evrysdi. Sees FY25 GAAP R&D and SG&A expense $805M-$835M; and non-GAAP R&D and SG&A expense $730M-$760M, excluding estimated non-cash, stock-based compensation expense of $75M.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTCT:
- PTC Therapeutics reports Q1 EPS $10.04 may not compare with consensus (7c)
- Controversial doctor Vinay Prasad named CBER director, STAT reports
- Optimistic Buy Rating for PTC Therapeutics Amid Market Skepticism and Promising Stage 2 Data
- Hold Rating for PTC Therapeutics Amid Mixed Clinical Results and Uncertain FDA Approval Prospects
- PTC Therapeutics price target lowered to $57 from $65 at RBC Capital